5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.51▼ | 1.54▼ | 1.54▼ | 1.42▼ | 1.25▲ |
MA10 | 1.47▼ | 1.40▼ | 1.40▼ | 1.34▲ | 1.56▼ |
MA20 | 1.33▲ | 1.28▲ | 1.24▲ | 1.24▲ | 1.80▼ |
MA50 | 1.24▲ | 1.44▼ | 1.51▼ | 1.65▼ | 2.23▼ |
MA100 | 1.58▼ | 1.74▼ | 1.77▼ | 1.85▼ | 2.51▼ |
MA200 | 1.86▼ | 2.01▼ | 2.05▼ | 2.15▼ | 3.04▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.012▲ | 0.047▲ | 0.054▲ | 0.060▲ | -0.049▼ |
RSI | 49.211▼ | 49.343▼ | 48.570▼ | 46.943▼ | 37.202▼ |
STOCH | 70.637 | 85.456▲ | 85.456▲ | 76.480 | 18.084▼ |
WILL %R | -58.979 | -58.586 | -58.586 | -43.671 | -68.122 |
CCI | -22.364 | 13.429 | 10.995 | 63.453 | -55.410 |
Friday, April 25, 2025 02:23 PM
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage ...
|
Thursday, April 24, 2025 03:25 AM
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Armata Pharmaceuticals, Inc. ARMP is a clinical-stage biotechnology company. The Zacks Consensus Estimate for its ...
|
Thursday, April 10, 2025 03:00 PM
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 1.50 | 1.50 | 1.345 | 1.345 | 13,220 |
30/04/25 | 1.58 | 1.69 | 1.5644 | 1.59 | 32,874 |
28/04/25 | 1.49 | 1.49 | 1.38 | 1.41 | 4,000 |
25/04/25 | 1.41 | 1.42 | 1.38 | 1.42 | 4,700 |
24/04/25 | 1.40 | 1.43 | 1.30 | 1.35 | 6,600 |
23/04/25 | 1.25 | 1.40 | 1.25 | 1.32 | 9,400 |
22/04/25 | 1.27 | 1.31 | 1.27 | 1.31 | 5,500 |
21/04/25 | 1.2125 | 1.30 | 1.194 | 1.24 | 9,075 |
17/04/25 | 1.25 | 1.25 | 1.20 | 1.23 | 7,000 |
16/04/25 | 1.15 | 1.23 | 1.11 | 1.18 | 3,300 |
|
|
||||
|
|
||||
|
|